top of page
Search

ADC Series (IX) ADC Manufacturing & CMC:How Antibody–Drug Conjugates Are Produced at Scale



ADC制造流程图，展示抗体生产、有效载荷合成、偶联过程、纯化及最终产品。背景为实验室装置，蓝白色调。





Executive Summary



Antibody–drug conjugates (ADCs) hold tremendous promise in both scientific innovation and clinical applications, but they also present significant challenges in manufacturing.


Compared to traditional biologics or small-molecule drugs, ADC production involves:


  • biologics (antibodies)

  • highly potent small molecules (payloads)

  • complex conjugation chemistry



As a result, ADC manufacturing and CMC (Chemistry, Manufacturing, and Controls) often become critical bottlenecks in drug development.


Many ADC programs:


  • are scientifically sound

  • show clinical signals

  • yet fail during scale-up or due to lack of product consistency



In this article, we explore:


  • ADC manufacturing workflows

  • DAR (Drug-to-Antibody Ratio) control

  • conjugation engineering

  • scale-up and GMP challenges

  • why CMC frequently limits ADC development





1. What Is ADC CMC?



CMC (Chemistry, Manufacturing, and Controls) represents the core framework for ensuring product quality and manufacturability in drug development.


For ADCs, CMC involves three key components:




Chemistry



  • payload structure

  • linker chemistry

  • conjugation reactions





Manufacturing



  • antibody production (typically using CHO cells)

  • payload synthesis

  • conjugation and purification





Controls



  • purity

  • DAR distribution

  • aggregation

  • stability




👉 For regulatory agencies such as the FDA and EMA:


CMC consistency and reproducibility are critical determinants for approval.




2. ADC Manufacturing Workflow



The ADC manufacturing process can be broadly divided into five key steps:




  1. Antibody Production



  • typically produced in CHO cells

  • includes upstream and downstream purification



👉 Similar to monoclonal antibody production, but with stricter quality requirements




  1. Payload Synthesis



ADC payloads are typically:


  • extremely cytotoxic (picomolar potency)



👉 Production requires:


  • high-containment facilities

  • specialized infrastructure





  1. Conjugation



This is the most critical step in ADC manufacturing.


👉 The payload is chemically linked to the antibody




  1. Purification



Objectives:


  • remove free (unconjugated) payload

  • remove unconjugated antibodies



👉 Purity directly impacts safety




  1. Formulation



  • buffer optimization

  • stability control





3. DAR (Drug-to-Antibody Ratio) Control





What Is DAR?



👉 The average number of payload molecules attached to each antibody




Why Does It Matter?



  • Low DAR → insufficient efficacy

  • High DAR → increased toxicity





Practical Challenge



ADCs are typically:


👉 heterogeneous mixtures


For example:


  • DAR 2 / 4 / 6 / 8 species may coexist



👉 Controlling the DAR distribution is critical




4. Challenges in Conjugation Chemistry





Traditional Methods




Lysine Conjugation



  • multiple reactive sites

  • high heterogeneity





Cysteine Conjugation



  • more controlled

  • widely used in modern ADCs





Next-Generation Approach: Site-Specific Conjugation



Advantages:


  • more uniform DAR

  • improved pharmacokinetics (PK)

  • more predictable toxicity



👉 This is a major industry trend




5. Scale-Up: The Largest Practical Challenge



Transitioning from:


👉 mg scale (laboratory)

to

👉 kg scale (commercial production)


introduces major challenges:




Reaction Reproducibility



  • consistency across batches





Batch Consistency



  • DAR distribution

  • purity





Stability



  • payload degradation

  • aggregation




👉 Many ADC programs fail at this stage




6. GMP and Safety Considerations





Highly Toxic Payloads



  • high handling risk

  • occupational safety concerns





Containment Requirements



  • isolator systems

  • closed processing systems





Cross-Contamination Risks



  • especially in multi-product facilities




👉 ADC manufacturing requires stricter controls than standard biologics




7. Analytical Characterization (Quality Control)



ADC quality control relies on multiple analytical techniques:




Common Methods



  • HPLC (purity)

  • SEC (aggregation)

  • LC-MS (DAR analysis)

  • CE-SDS (structural characterization)





Why Is This Important?



👉 ADCs are complex mixtures, not single homogeneous molecules




8. Why Do ADCs Fail at the CMC Stage?



Common reasons include:




  1. Mismatch Between Design and Manufacturability



👉 Research design ≠ manufacturable design




  1. Non-Scalable Processes



👉 Successful in the lab, but fail during scale-up




  1. Insufficient QC Methods



👉 Inability to accurately measure DAR or impurities




  1. High Cost



👉 Payload synthesis and manufacturing are extremely expensive



👉 CMC challenges are a major reason many ADC pipelines fail




9. The Future: Platform-Based ADC Manufacturing



Emerging trends include:




Platform Processes



  • standardized conjugation

  • modular design





Automation



  • reduces human variability





Continuous Manufacturing



  • improves efficiency and consistency




👉 ADCs are evolving from individual products into manufacturing platforms




From Molecule to Manufacturing | LuTra Studio Consulting



ADC manufacturing is inherently a cross-disciplinary challenge involving:


  • chemistry

  • process engineering

  • quality control

  • regulatory strategy



Many teams:


👉 have strong molecular design

👉 but lack manufacturability


At LuTra Studio, we help teams:


  • design scalable ADC platforms

  • build robust CMC strategies

  • evaluate DAR and process risks

  • coordinate with CDMOs and development workflows



so that ADC programs are not only scientifically feasible, but:


👉 manufacturable at scale and commercially viable



Comments

bottom of page